Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | Director | September 30, 2026 | October 03, 2026 |
| GE HealthCare Technologies Inc.GEHC · Entity 1711 | Director · President and CEO | September 03, 2026 | September 04, 2026 |
| GENERAL ELECTRIC COGE · Entity 2813 | Senior Vice President | March 01, 2022 | March 04, 2022 |
| INTEGRA LIFESCIENCES HOLDINGS CORPIART · Entity 2707 | Director · President & CEO | September 02, 2021 | September 07, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRISTOL MYERS SQUIBB CO
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Share UnitsSEC Table II · derivative / convertible security | Direct | 74,077.176 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 560.897 · Balance 74,077.176 F1: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.
F2: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
GE HealthCare Technologies Inc.
Report date September 03, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01 per shareSEC Table I · non-derivative | Direct | 241,606 |
Reported balance
After 2026-09-03 transaction · row 1
1 source rowRow 1 · 2026-09-03 · Tax withholding · Disposed 6,303 · Balance 241,606 F1: Withholding of shares of GE HealthCare Technologies Inc. common stock to satisfy tax withholding obligations in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Withholding of shares of GE HealthCare Technologies Inc. common stock to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
GENERAL ELECTRIC CO
Report date March 01, 2022 · Filed March 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 14,443 |
Reported balance
After 2022-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-01 · Grant · Acquired 14,443 · Balance 14,443 F1: 1 for 1 F2: The Restricted Stock Units vest and the Stock Options become exercisable, in two equal installments of 50% each on the second and third anniversary of the grant date |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $92.23 · Expires 2032-03-01 | Direct | 63,044 |
Reported balance
After 2022-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-03-01 · Grant · Acquired 63,044 · Balance 63,044 F2: The Restricted Stock Units vest and the Stock Options become exercisable, in two equal installments of 50% each on the second and third anniversary of the grant date |
Filing footnotes · ownership attribution and instrument terms
F1: 1 for 1
F2: The Restricted Stock Units vest and the Stock Options become exercisable, in two equal installments of 50% each on the second and third anniversary of the grant date
INTEGRA LIFESCIENCES HOLDINGS CORP
Report date September 02, 2021 · Filed September 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 216,713 |
Ending reported balance
After 2021-09-03 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2021-09-02 · Exercise / conversion · Acquired 71,829 · Balance 288,542 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Row 2 · 2021-09-02 · Sale · Disposed 71,829 · Balance 216,713 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F2: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $75.34 to $76.465 per share of common stock. Row 3 · 2021-09-03 · Exercise / conversion · Acquired 46,605 · Balance 263,318 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Row 4 · 2021-09-03 · Sale · Disposed 46,605 · Balance 216,713 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F3: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $75.40 to $76.09 per share of common stock. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.88 · Expires 2022-03-06 | Direct | 46,605 |
Reported balance
After 2021-09-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-09-02 · Exercise / conversion · Disposed 71,829 · Balance 46,605 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F4: One-third of the stock options vested on the first anniversary of the grant date of March 6, 2014 and thereafter with respect to the remaining two-thirds which vested in monthly installments through the third anniversary of the grant date. F5: These options were previously reported as covering 56,727 shares at an exercise price of $48.27 per share, but were adjusted pursuant to the anti-dilution provisions of the award in connection with the separation of SeaSpine Holdings Corporation on July 1, 2015. F6: In accordance with terms of the stock option plan, the exercise price of the options and the number of shares subject to the options have been adjusted to reflect the two-for-one stock split of the Issuer's common stock that occurred on December 21, 2016. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.88 · Expires 2022-03-06 | Direct | 0 |
Reported balance
After 2021-09-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-09-03 · Exercise / conversion · Disposed 46,605 · Balance 0 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F4: One-third of the stock options vested on the first anniversary of the grant date of March 6, 2014 and thereafter with respect to the remaining two-thirds which vested in monthly installments through the third anniversary of the grant date. F5: These options were previously reported as covering 56,727 shares at an exercise price of $48.27 per share, but were adjusted pursuant to the anti-dilution provisions of the award in connection with the separation of SeaSpine Holdings Corporation on July 1, 2015. F6: In accordance with terms of the stock option plan, the exercise price of the options and the number of shares subject to the options have been adjusted to reflect the two-for-one stock split of the Issuer's common stock that occurred on December 21, 2016. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.
F2: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $75.34 to $76.465 per share of common stock.
F3: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $75.40 to $76.09 per share of common stock.
F4: One-third of the stock options vested on the first anniversary of the grant date of March 6, 2014 and thereafter with respect to the remaining two-thirds which vested in monthly installments through the third anniversary of the grant date.
F5: These options were previously reported as covering 56,727 shares at an exercise price of $48.27 per share, but were adjusted pursuant to the anti-dilution provisions of the award in connection with the separation of SeaSpine Holdings Corporation on July 1, 2015.
F6: In accordance with terms of the stock option plan, the exercise price of the options and the number of shares subject to the options have been adjusted to reflect the two-for-one stock split of the Issuer's common stock that occurred on December 21, 2016.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2022 Filed Mar 4, 2022 01:05 UTC | GENERAL ELECTRIC CO GE · Entity 2813 | GrantEmployee Stock Option (right to buy) · Derivative | 63,044 | $0.00 Strike: $92.23 | $0.00 |
DisclosureSEC source: 0001062993-22-006738 · form4.xml · derivative · entry 2 Arduini Peter J · CIK 0001323134 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,044 Underlying: Common Stock · 63,044 shares Expires 2032-03-01 F2 · derivative.exercise_date: The Restricted Stock Units vest and the Stock Options become exercisable, in two equal installments of 50% each on the second and third anniversary of the grant date Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 01:05 UTC | GENERAL ELECTRIC CO GE · Entity 2813 | GrantRestricted Stock Units · Derivative | 14,443 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-006738 · form4.xml · derivative · entry 1 Arduini Peter J · CIK 0001323134 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,443 Underlying: Common Stock · 14,443 shares Expires not disclosed F1 · derivative.exercise_price: 1 for 1 F2 · derivative.exercise_date: The Restricted Stock Units vest and the Stock Options become exercisable, in two equal installments of 50% each on the second and third anniversary of the grant date F2 · derivative.expiration_date: The Restricted Stock Units vest and the Stock Options become exercisable, in two equal installments of 50% each on the second and third anniversary of the grant date Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 23:03 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 3,067.955 | $65.19 | $199,999.99 |
DisclosureSEC source: 0000014272-22-000039 · wf-form4_164392940895408.xml · derivative · entry 1 Arduini Peter J · CIK 0001323134 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,803.969 Underlying: Common Stock, $0.10 par value · 3,067.955 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 23:23 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 521.251 | $62.35 | $32,500.00 |
DisclosureSEC source: 0000014272-22-000019 · wf-form4_164133859017977.xml · derivative · entry 1 Arduini Peter J · CIK 0001323134 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,450.645 Underlying: Common Stock, $0.10 par value · 521.251 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 20:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 549.265 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-21-000220 · wf-form4_163312029280764.xml · derivative · entry 1 Arduini Peter J · CIK 0001323134 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,648.418 Underlying: Common Stock, $0.10 par value · 549.265 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| September 03, 2021 Filed Sep 7, 2021 20:12 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 46,605 | $0.00 Strike: $20.88 | $0.00 |
DisclosureSEC source: 0001209191-21-054970 · doc4.xml · derivative · entry 6 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,605 shares Expires 2022-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F4 · derivative.exercise_date: One-third of the stock options vested on the first anniversary of the grant date of March 6, 2014 and thereafter with respect to the remaining two-thirds which vested in monthly installments through the third anniversary of the grant date. F5 · balance_after: These options were previously reported as covering 56,727 shares at an exercise price of $48.27 per share, but were adjusted pursuant to the anti-dilution provisions of the award in connection with the separation of SeaSpine Holdings Corporation on July 1, 2015. F6 · balance_after: In accordance with terms of the stock option plan, the exercise price of the options and the number of shares subject to the options have been adjusted to reflect the two-for-one stock split of the Issuer's common stock that occurred on December 21, 2016. Read SEC document |
| September 03, 2021 Filed Sep 7, 2021 20:12 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 46,605 | $75.75 | $3,530,459.24 |
DisclosureSEC source: 0001209191-21-054970 · doc4.xml · nonDerivative · entry 4 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,713 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F3 · price: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $75.40 to $76.09 per share of common stock. Read SEC document |
| September 03, 2021 Filed Sep 7, 2021 20:12 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 46,605 | $20.88 | $973,112.40 |
DisclosureSEC source: 0001209191-21-054970 · doc4.xml · nonDerivative · entry 3 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,318 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:12 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 71,829 | $0.00 Strike: $20.88 | $0.00 |
DisclosureSEC source: 0001209191-21-054970 · doc4.xml · derivative · entry 5 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,605 Underlying: Common Stock · 71,829 shares Expires 2022-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F4 · derivative.exercise_date: One-third of the stock options vested on the first anniversary of the grant date of March 6, 2014 and thereafter with respect to the remaining two-thirds which vested in monthly installments through the third anniversary of the grant date. F5 · derivative.exercise_date: These options were previously reported as covering 56,727 shares at an exercise price of $48.27 per share, but were adjusted pursuant to the anti-dilution provisions of the award in connection with the separation of SeaSpine Holdings Corporation on July 1, 2015. F5 · derivative.underlying_shares: These options were previously reported as covering 56,727 shares at an exercise price of $48.27 per share, but were adjusted pursuant to the anti-dilution provisions of the award in connection with the separation of SeaSpine Holdings Corporation on July 1, 2015. F6 · derivative.underlying_shares: In accordance with terms of the stock option plan, the exercise price of the options and the number of shares subject to the options have been adjusted to reflect the two-for-one stock split of the Issuer's common stock that occurred on December 21, 2016. F5 · balance_after: These options were previously reported as covering 56,727 shares at an exercise price of $48.27 per share, but were adjusted pursuant to the anti-dilution provisions of the award in connection with the separation of SeaSpine Holdings Corporation on July 1, 2015. F6 · balance_after: In accordance with terms of the stock option plan, the exercise price of the options and the number of shares subject to the options have been adjusted to reflect the two-for-one stock split of the Issuer's common stock that occurred on December 21, 2016. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:12 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 71,829 | $75.97 | $5,456,662.37 |
DisclosureSEC source: 0001209191-21-054970 · doc4.xml · nonDerivative · entry 2 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,713 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F2 · price: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $75.34 to $76.465 per share of common stock. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:12 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 71,829 | $20.88 | $1,499,789.52 |
DisclosureSEC source: 0001209191-21-054970 · doc4.xml · nonDerivative · entry 1 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 21:18 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 507.35 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-21-000176 · wf-form4_162517425421264.xml · derivative · entry 1 Arduini Peter J · CIK 0001323134 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,862.42 Underlying: Common Stock, $0.10 par value · 507.35 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 17:23 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 574.212 | $63.13 | $36,250.00 |
DisclosureSEC source: 0000014272-21-000122 · wf-form4_161738419128553.xml · derivative · entry 1 Arduini Peter J · CIK 0001323134 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,111.633 Underlying: Common Stock, $0.10 par value · 574.212 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 13, 2021 Filed Mar 16, 2021 20:22 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionRestricted Stock Units · Derivative | 368 | $68.10 Strike: $0.00 | $25,060.80 |
DisclosureSEC source: 0001209191-21-020787 · doc4.xml · derivative · entry 11 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 552,716 Underlying: Common Stock · 368 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The award was a restricted stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/20 of which the first installment vested on 3/13/21 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. F5 · derivative.exercise_date: The award was a restricted stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/20 of which the first installment vested on 3/13/21 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. F5 · derivative.expiration_date: The award was a restricted stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/20 of which the first installment vested on 3/13/21 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. Read SEC document |
| March 13, 2021 Filed Mar 16, 2021 20:22 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionRestricted Stock Units · Derivative | 272 | $68.10 Strike: $0.00 | $18,523.20 |
DisclosureSEC source: 0001209191-21-020787 · doc4.xml · derivative · entry 10 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 553,084 Underlying: Common Stock · 272 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The award was a restricted stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/19 of which the second installment vested on 3/13/21 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. F4 · derivative.exercise_date: The award was a restricted stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/19 of which the second installment vested on 3/13/21 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. F4 · derivative.expiration_date: The award was a restricted stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/19 of which the second installment vested on 3/13/21 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. Read SEC document |
| March 13, 2021 Filed Mar 16, 2021 20:22 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionRestricted Stock Units · Derivative | 258 | $68.10 Strike: $0.00 | $17,569.80 |
DisclosureSEC source: 0001209191-21-020787 · doc4.xml · derivative · entry 9 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 553,356 Underlying: Common Stock · 258 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The award was a restricted stock unit award which vested in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/18 of which the third installment vested on 3/13/21 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. F3 · derivative.exercise_date: The award was a restricted stock unit award which vested in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/18 of which the third installment vested on 3/13/21 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. F3 · derivative.expiration_date: The award was a restricted stock unit award which vested in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/18 of which the third installment vested on 3/13/21 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. Read SEC document |
| March 13, 2021 Filed Mar 16, 2021 20:22 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 368 | $68.10 | $25,060.80 |
DisclosureSEC source: 0001209191-21-020787 · doc4.xml · nonDerivative · entry 6 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,713 Read SEC document |
| March 13, 2021 Filed Mar 16, 2021 20:22 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 368 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-020787 · doc4.xml · nonDerivative · entry 5 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2021 Filed Mar 16, 2021 20:22 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 272 | $68.10 | $18,523.20 |
DisclosureSEC source: 0001209191-21-020787 · doc4.xml · nonDerivative · entry 4 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,713 Read SEC document |
| March 13, 2021 Filed Mar 16, 2021 20:22 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 272 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-020787 · doc4.xml · nonDerivative · entry 3 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2021 Filed Mar 16, 2021 20:22 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 258 | $68.10 | $17,569.80 |
DisclosureSEC source: 0001209191-21-020787 · doc4.xml · nonDerivative · entry 2 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,713 Read SEC document |
| March 13, 2021 Filed Mar 16, 2021 20:22 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 258 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-020787 · doc4.xml · nonDerivative · entry 1 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,971 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:22 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantRestricted Stock Units · Derivative | 22,027 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-020787 · doc4.xml · derivative · entry 8 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 553,614 Underlying: Common Stock · 22,027 shares Expires not disclosed F2 · derivative.exercise_price: The award was a restricted stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/12/2021 which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. This award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. F2 · derivative.exercise_date: The award was a restricted stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/12/2021 which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. This award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. F2 · derivative.expiration_date: The award was a restricted stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/12/2021 which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. This award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:22 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 66,402 | $0.00 Strike: $68.10 | $0.00 |
DisclosureSEC source: 0001209191-21-020787 · doc4.xml · derivative · entry 7 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,402 Underlying: Common Stock · 66,402 shares Expires 2029-03-13 F1 · derivative.exercise_date: The grant will vest as to one-third of the shares on the first anniversary of the grant date of 3/12/2021 and thereafter in monthly installments through the following twenty-four months. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 21:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 22,786 | $0.00 Strike: $15.79 | $0.00 |
DisclosureSEC source: 0001209191-21-007204 · doc4.xml · derivative · entry 3 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,786 shares Expires 2021-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F3 · derivative.exercise_date: One-third of the stock options vested on the first anniversary of the grant date which is May 22, 2013 and thereafter with respect to the remaining two-thirds which vested in monthly installments through the 3rd anniversary of the grant date. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 21:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 22,786 | $66.16 | $1,507,442.01 |
DisclosureSEC source: 0001209191-21-007204 · doc4.xml · nonDerivative · entry 2 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,713 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F2 · price: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $65.11 to $66.82. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 21:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 22,786 | $15.79 | $359,790.94 |
DisclosureSEC source: 0001209191-21-007204 · doc4.xml · nonDerivative · entry 1 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:18 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 3,054.171 | $62.21 | $189,999.98 |
DisclosureSEC source: 0000014272-21-000051 · wf-form4_161239786825428.xml · derivative · entry 1 Arduini Peter J · CIK 0001323134 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,537.421 Underlying: Common Stock, $0.10 par value · 3,054.171 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 31, 2020 Filed Jan 6, 2021 01:09 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 584.395 | $62.03 | $36,250.02 |
DisclosureSEC source: 0000014272-21-000016 · wf-form4_160989536855328.xml · derivative · entry 1 Arduini Peter J · CIK 0001323134 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,260.656 Underlying: Common Stock, $0.10 par value · 584.395 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 18, 2020 Filed Dec 21, 2020 21:08 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $15.79 | $0.00 |
DisclosureSEC source: 0001209191-20-064620 · doc4.xml · derivative · entry 3 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,786 Underlying: Common Stock · 45,000 shares Expires 2021-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F3 · derivative.exercise_date: One-third of the stock options vested on the first anniversary of the grant date which is May 22, 2013 and thereafter with respect to the remaining two-thirds which vested in monthly installments through the 3rd anniversary of the grant date. F4 · balance_after: This option was previously reported as covering 32,468 shares at an exercise price of $36.50 per share, but was adjusted pursuant to the antidilution provisions of the award in connection with the spin-off of SeaSpine Holdings Corporation on July 1, 2015. F5 · balance_after: In accordance with the terms of the stock option plan, the exercise price of the option and number of shares subject to the option have been adjusted to eflect the two-for-one stock split that occurred on December 21, 2016. Read SEC document |
| December 18, 2020 Filed Dec 21, 2020 21:08 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 45,000 | $61.97 | $2,788,780.50 |
DisclosureSEC source: 0001209191-20-064620 · doc4.xml · nonDerivative · entry 2 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,713 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F2 · price: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $61.50 to $62.74. Read SEC document |
| December 18, 2020 Filed Dec 21, 2020 21:08 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 45,000 | $15.79 | $710,550.00 |
DisclosureSEC source: 0001209191-20-064620 · doc4.xml · nonDerivative · entry 1 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 20:30 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 601.261 | $60.29 | $36,250.03 |
DisclosureSEC source: 0000014272-20-000265 · wf-form4_160167064183367.xml · derivative · entry 1 Arduini Peter J · CIK 0001323134 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,468.481 Underlying: Common Stock, $0.10 par value · 601.261 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 21:02 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 616.497 | $58.80 | $36,250.02 |
DisclosureSEC source: 0000014272-20-000215 · wf-form4_159372365790382.xml · derivative · entry 1 Arduini Peter J · CIK 0001323134 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,664.192 Underlying: Common Stock, $0.10 par value · 616.497 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 20:50 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 650.341 | $55.74 | $36,250.01 |
DisclosureSEC source: 0000014272-20-000141 · wf-form4_158586060019816.xml · derivative · entry 1 Arduini Peter J · CIK 0001323134 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,854.626 Underlying: Common Stock, $0.10 par value · 650.341 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantRestricted Stock Units · Derivative | 41,485 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-019550 · doc4.xml · derivative · entry 14 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 545,415 Underlying: Common Stock · 41,485 shares Expires not disclosed F5 · derivative.exercise_price: The award was a restricted stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/2020 which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. This award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. F5 · derivative.exercise_date: The award was a restricted stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/2020 which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. This award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. F5 · derivative.expiration_date: The award was a restricted stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/2020 which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. This award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionRestricted Stock Units · Derivative | 272 | $43.39 Strike: $0.00 | $11,802.08 |
DisclosureSEC source: 0001209191-20-019550 · doc4.xml · derivative · entry 13 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 503,930 Underlying: Common Stock · 272 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The award was a restricted stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/19 of which the first installment vested on 3/13/20 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. F4 · derivative.exercise_date: The award was a restricted stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/19 of which the first installment vested on 3/13/20 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. F4 · derivative.expiration_date: The award was a restricted stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/19 of which the first installment vested on 3/13/20 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionRestricted Stock Units · Derivative | 258 | $43.39 Strike: $0.00 | $11,194.62 |
DisclosureSEC source: 0001209191-20-019550 · doc4.xml · derivative · entry 12 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,202 Underlying: Common Stock · 258 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The award was a restricted stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/18 of which the second installment vested on 3/13/20 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. F3 · derivative.exercise_date: The award was a restricted stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/18 of which the second installment vested on 3/13/20 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. F3 · derivative.expiration_date: The award was a restricted stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/18 of which the second installment vested on 3/13/20 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionRestricted Stock Units/Contract Stock · Derivative | 290 | $43.39 Strike: $0.00 | $12,583.10 |
DisclosureSEC source: 0001209191-20-019550 · doc4.xml · derivative · entry 11 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,460 Underlying: Common Stock · 290 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/17 of which the third installment vested on 3/13/20 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation F2 · derivative.exercise_date: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/17 of which the third installment vested on 3/13/20 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation F2 · derivative.expiration_date: The award was a contract stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/17 of which the third installment vested on 3/13/20 and which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 92,096 | $0.00 Strike: $43.39 | $0.00 |
DisclosureSEC source: 0001209191-20-019550 · doc4.xml · derivative · entry 10 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,096 Underlying: Common Stock · 92,096 shares Expires 2028-03-13 F1 · derivative.exercise_date: The grant will vest as to one-third of the shares on the first anniversary of the grant date of 3/13/2020 and thereafter in monthly installments through the following twenty-four months. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 12,041 | $43.39 | $522,458.99 |
DisclosureSEC source: 0001209191-20-019550 · doc4.xml · nonDerivative · entry 9 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,713 Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 7,085 | $43.39 | $307,418.15 |
DisclosureSEC source: 0001209191-20-019550 · doc4.xml · nonDerivative · entry 8 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,754 Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 6,736 | $43.39 | $292,275.04 |
DisclosureSEC source: 0001209191-20-019550 · doc4.xml · nonDerivative · entry 7 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,839 Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 272 | $43.39 | $11,802.08 |
DisclosureSEC source: 0001209191-20-019550 · doc4.xml · nonDerivative · entry 6 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,575 Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 272 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-019550 · doc4.xml · nonDerivative · entry 5 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,847 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 258 | $43.39 | $11,194.62 |
DisclosureSEC source: 0001209191-20-019550 · doc4.xml · nonDerivative · entry 4 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,575 Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 258 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-019550 · doc4.xml · nonDerivative · entry 3 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 290 | $43.39 | $12,583.10 |
DisclosureSEC source: 0001209191-20-019550 · doc4.xml · nonDerivative · entry 2 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,575 Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 290 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-019550 · doc4.xml · nonDerivative · entry 1 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,865 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2020 Filed Mar 27, 2020 20:34 UTC Amendment | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantRestricted Stock Units · Derivative | 27,657 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-021394 · doc4a.xml · derivative · entry 2 Arduini Peter J · CIK 0001323134 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 531,587 Underlying: Common Stock · 27,657 shares Expires not disclosed F3 · derivative.exercise_price: The award was a restricted stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/2020 which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. This award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. F1 · shares: This amendment to the Form 4, originally filed on March 17, 2020, is being filed to correct the number of options and shares awarded and beneficially owned due to an administrative error in the original filing. F3 · derivative.exercise_date: The award was a restricted stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/2020 which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. This award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. F3 · derivative.expiration_date: The award was a restricted stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 3/13/2020 which shall be delivered to Mr. Arduini within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. This award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. F1 · derivative.underlying_shares: This amendment to the Form 4, originally filed on March 17, 2020, is being filed to correct the number of options and shares awarded and beneficially owned due to an administrative error in the original filing. F1 · balance_after: This amendment to the Form 4, originally filed on March 17, 2020, is being filed to correct the number of options and shares awarded and beneficially owned due to an administrative error in the original filing. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.